A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors

Investigational New Drugs

Volumn 32, Issue 3, 2014, Pages 518-525

  Von Mehren, Margaret ^a   Britten, Carolyn D ^b,c   Pieslor, Peter ^d,e   Saville, Wayne ^d,f   Vassos, Artemios ^d   Harris, Sarah ^d,g   Galluppi, Gerald R ^d   Darif, Mohamed ^d,h   Wainberg, Zev A ^b   Cohen, Roger B ^a,i   Leong, Stephen ^j  

^a FOX CHASE CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d BIOGEN   (United States)

^e AMGEN INC   (United States)

^f Genoptix Inc   (United States)

^g Novartis   (United States)

^h Sangrat   (United States)

ⁱ HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^j UNIVERSITY OF COLORADO CANCER CENTER   (United States)

more..

Author keywords

Antibody; FDG PET; IGF 1R; Phase I; Sarcoma

Indexed keywords

BIIB 022; MONOCLONAL ANTIBODY; SOMATOMEDIN C RECEPTOR; SOMATOMEDIN C RECEPTOR MONOCLONAL ANTIBODY BIIB022; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BIIB022;

ADRENAL CORTEX CARCINOMA; ADULT; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CANCER GROWTH; CANCER MORTALITY; CANCER RECURRENCE; CLINICAL ARTICLE; COHORT ANALYSIS; COLORECTAL CANCER; DEEP VEIN THROMBOSIS; DIZZINESS; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DYSPNEA; ENDOMETRIUM CARCINOMA; EWING SARCOMA; FATIGUE; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; LIPOSARCOMA; LUNG CANCER; LUNG CONGESTION; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCLE SPASM; NAUSEA; PANCREAS CANCER; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; QT PROLONGATION; RETROPERITONEAL SARCOMA; RHABDOMYOSARCOMA; SARCOMA; SOLID TUMOR; SPINDLE CELL CARCINOMA; SYNOVIAL SARCOMA; AGED; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; DRUG RESISTANCE; FEMALE; IMMUNOLOGY; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; TUMOR RECURRENCE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; RECEPTOR, IGF TYPE 1;

EID: 84904673413     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-014-0064-y     Document Type: Article

References (19)

1. Baserga R (2005) The insulin-like growth factor-I receptor as a target for cancer therapy. Expert Opin Ther Targets 9:753-768
2. Larsson O, Girnita A, Girnita L (2005) Role of insulin-like growth factor 1 receptor signalling in cancer. Br J Cancer 92:2097-2101 (Pubitemid 40966242)
3. Pollak MN, Schernhammer ES, Hankinson SE (2004) Insulin-like growth factors and neoplasia. Nat Rev Cancer 4:505-518 (Pubitemid 38868620)
4. Chong YM, Subramanian A, Sharma AK, Mokbel K (2007) The potential clinical applications of insulin-like growth factor-1 ligand in human breast cancer. Anti-Cancer Res 27:1617-1624 (Pubitemid 46807246)
5. Peyrat JP, Bonneterre J, Hecquet B et al (1993) Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer. Eur J Cancer 29A:492-497 (Pubitemid 23036292)
6. Hassan AB, Macaulay VM (2002) The insulin-like growth factor system as a therapeutic target in colorectal cancer. Ann Oncol 13:349-356 (Pubitemid 34704993)
7. Zhang L, Zhou W, Velculescu VE et al (1997) Gene expression profiles in normal and cancer cells. Science 276:1268-1272 (Pubitemid 27227367)
8. Doern A, Cao X, Sereno A et al (2009) Characterization of inhibitory anti-IGF-1R antibodies with different epitope specificity and ligand blocking properties: implications for mechanism of action in vivo. J Biol Chem 284:10254-10267
9. Biogen-Idec Investigator Brochure, Version 6, 2010
10. Young H, Baum R, Cremerius U et al (1999) Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 35:1773-1782 (Pubitemid 29512308)
11. Tolcher AW, Sarantopoulos J, Patnaik A et al (2009) Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol 27:5800-5807
12. Kurzrock R, Patnaik A, Aisner J et al (2010) A phase i study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors. Clin Cancer Res 16:2458-2465
13. Atzori F, Tabernero J, Cervantes A et al (2011) A phase I pharmacokinetic and pharmacodynamic study of Dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res 17:6304-6312
14. Pappo AS, Patel SR, Crowley J et al (2011) R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing Sarcoma family of tumors: results of a phase II sarcoma alliance for research through collaboration study. J Clin Oncol 34:4541-4547
15. Tap WD, Demetri GD, Barnette P (2012) Phase II study of Ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic ewing family tumors or desmoplastic small round cell tumors. J Clin Oncol 30:1849-1856
16. Crago AM, Singer S (2011) Clinical and molecular approaches to well differentiated and dedifferentiated liposarcoma. Curr Opin Oncol 23:373-378
17. Bono P, Krause A, von Mehren M et al (2004) Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib. Blood 103:2929-2935 (Pubitemid 38451662)
18. DePrimo SE, Bello CL, Smeraglia J et al (2007) Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med 5:32
19. Schwartz GK, Tap WD, Qin LX et al. (2012) A phase II multicenter study of the IGF-1 receptor antibody cixutumumab (A12) and the mTOR inhibitor temsirolimus (TEM) in patients (pts) with refractory IGF-1R positive (+) and negative (-) bone and soft tissue sarcomas (STS). J Clin Oncol 30:(suppl; abstr 10003)